Biologic and Clinical Perspectives on Thyroid Cancer | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Mutations play a fundamental role in the development of cancer, and many create targetable
vulnerabilities. There are both public health and basic science benefits from the …

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive
Papillary Thyroid Cancer With Highest Recurrence - PMC Back to Top Skip to main content NIH …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Importance BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its
role in PTC-related patient mortality has not been established. Objective To investigate the …

The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Background About half of patients with papillary thyroid cancer have tumours with activating
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …

Abstract Mutations 1 295 228 C> T and 1 295 250 C> T (termed C228T and C250T
respectively), corresponding to− 124 C> T and− 146 C> T from the translation start site in the …